Dr. Brentjens on Challenges of CAR-Modified T Cells

Video

Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the challenges associated with CAR-modified T cells.

Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the challenges associated with CAR-modified T cells.

Getting CAR-modified T cells into the clinic was the first challenge, Brentjens says, but that is less of an obstacle now.

Now, physicians and researchers must cope with the side effects of CAR-modified T cells as well as how to address diseases where they do not work. A third challenges exists in expanding this therapy to other types of cancers. Brentjens believes investigators will focus on identifying target proteins or carbohydrates on the tumor cell surface for different tumor types. This will allow for the exploration of CAR-modified T cells in solid tumors and other types of hematologic malignancies.

Related Videos
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD